Introduction to General Toxicity Evaluation of Monoclonal Antibodies
On May 13, 2026, the Pharmaceuticals and Medical Devices Agency (PMDA) published an Early Consideration document outlining its current thinking on the general toxicity evaluation of conventional monoclonal antibodies. The document reflects growing interest in reducing animal use through the principles of the 3Rs (Reduce, Refine, Replace), while incorporating advances in New Approach Methodologies (NAMs) and Weight of Evidence (WOE) approaches. As an Early Consideration, it represents PMDA’s current scientific perspective and may evolve as further experience and evidence are accumulated.
Background: Why PMDA Is Reconsidering Long-Term Toxicity Studies
Monoclonal antibodies exhibit high target specificity and species specificity. In many cases, non-human primates are the only relevant animal species in which meaningful pharmacological activity can be evaluated. Historically, long-term repeated-dose toxicity studies in monkeys have been conducted to support clinical development. However, accumulated experience suggests that these studies often provide limited new information beyond predictable pharmacology-related findings and immunogenicity observations.
Several retrospective analyses have indicated that 3-month toxicity studies frequently provide sufficient safety information for conventional monoclonal antibodies. In parallel, both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have recently promoted more streamlined approaches to nonclinical safety testing and increased use of NAMs.
Adoption of a Weight of Evidence (WOE) Approach
A central concept introduced in the document is the use of a Weight of Evidence (WOE) approach. Rather than relying on a single study, sponsors are encouraged to integrate multiple sources of information when evaluating toxicity risks. These sources may include:
The objective is to make scientifically justified decisions regarding the extent of nonclinical testing required for a specific development program.
Considerations for Waiving 6-Month Monkey Toxicity Studies
PMDA acknowledges that a 6-month repeated-dose toxicity study in monkeys may not always provide meaningful additional information beyond a 3-month study. Therefore, sponsors are encouraged to assess the necessity of long-term studies using a WOE framework.
A 6-month study is more likely to be needed when:
Conversely, when these concerns do not apply, or when immunogenicity limits interpretation of long-term monkey studies, the scientific value of an additional 6-month study may be limited.
Utilization of New Approach Methodologies (NAMs)
The document strongly encourages consideration of New Approach Methodologies (NAMs) as part of toxicity evaluations. NAMs include a broad range of non-animal technologies such as:
PMDA views NAM-generated information as potentially valuable components of a WOE-based safety assessment and recognizes their increasing role in modern nonclinical development.
Approach When No Relevant Animal Species Exists
The document also addresses monoclonal antibodies for which no pharmacologically relevant animal species is available. This situation is increasingly common for highly human-specific targets.
In such cases, PMDA refers to the principles described in ICH S6(R1), including consideration of:
The agency emphasizes maximizing all available evidence and assessing risk through a WOE framework rather than relying solely on conventional animal testing.
Human-Specific Targets and Target Safety Assessment
For monoclonal antibodies directed against targets that exist only in humans, PMDA highlights the potential value of Target Safety Assessment. This approach integrates:
Such information can help predict potential on-target toxicities and guide risk management strategies when traditional animal models are of limited relevance.
Alignment with Global Regulatory Trends
The PMDA document reflects increasing global momentum toward modernization of nonclinical safety assessments for biologics. Similar initiatives have recently been promoted by both FDA and EMA, including efforts to reduce reliance on animal studies and expand the use of scientifically justified alternative approaches.
By explicitly recognizing WOE-based decision making, NAM-derived data, and the limited value of certain long-term monkey studies, PMDA is moving toward a more flexible, science-driven framework that aligns with international regulatory thinking.
Conclusion
This Early Consideration signals an important evolution in PMDA’s approach to the nonclinical safety evaluation of conventional monoclonal antibodies. Rather than routinely requiring lengthy animal studies, PMDA encourages risk-based decision making using a Weight of Evidence framework that integrates traditional toxicity data, emerging NAM technologies, target biology, and available clinical experience.
The document supports the principles of the 3Rs while maintaining a commitment to patient safety and scientific rigor. For sponsors developing monoclonal antibodies, it creates opportunities to discuss more efficient nonclinical development strategies with PMDA and potentially reduce reliance on long-term non-human primate studies.
Reference